SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : 2008 Biotech Stock Picking for Charity -- Ignore unavailable to you. Want to Upgrade?

To: idos who wrote (111)1/14/2008 8:35:01 AM
From: kenhott  Read Replies (1) | Respond to of 322
 
Of course patent outcomes are hard to figure out. But as far as I know, Altace's patent was troubled by the fact that the challenger was able to show other similar ACEs with similar structures to Altace. And that AVS didn't learn anything unexpected with the discovery of the Altace structure. So that goes to the problem of the discovery not been a new idea.



To: idos who wrote (111)1/18/2008 7:49:48 PM
From: rkrw  Read Replies (3) | Respond to of 322
 
Multiple settlements can be done. I never thought ceph would be able to do it with provigil, but they settled 4 of them and two different types of challenges, invalidity and non infringing.

When do the xopenex patents expire?

Lunesta has a pretty short patent life I believe, maybe just another few years left. 2011 or 2013 I think.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News